244 results about "Glucuronate" patented technology

The invention discloses a beta-glucuronidase inhibitor composition as well as a preparation method and application thereof. The composition is prepared from the following substances: ursolic acid, procyanidine, icariin, curcumin, epigallocatechin gallate and glycyrrhetinic acid. The beta-glucuronidase inhibitor composition has a broad-spectrum and good inhibition effect, the preparation method is simple, large-scale production is easy, and the inhibitor with a natural source is higher in use compliance, lower in toxic and side effects and more suitable for developing intestinal health products and has an application prospect.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The present invention belongs to the field of biotechnology, and specifically relates to a GmSGT2 gene related to plant height and branch development, and a mutant thereof and the use thereof. A Glycine max mutant having fewer branches and decreased plant height is obtained by means of EMS mutagenesis, and a target gene thereof that is located by means of a map-based cloning technique is a GmSGT2 gene of Hedou 12. It is found through searching that the gene encodes soyasapogenol B glucuronide galactosyltransferase, and can galactosylate soyasapogenol B monoglucuronide, thereby affecting the plant height of Glycine max and reducing the branches of Glycine max. Therefore, the GmSGT2 mutant can be used for cultivating dwarf high-yield Glycine max varieties, and is of great significance in the breeding of ideal plant types of Glycine max and research on important agronomic traits of plants. The mutant has broad application prospects and great research value with regard to understanding the plant height and branch regulation mechanism of Glycine max and improving the process of Glycine max breeding; and can provide an excellent germplasm resource stock for regulating the close planting and high-yield breeding of Glycine max.

The invention belongs to the technical field of biomedicine, and discloses a Parkinson's disease specific plasma metabolism marker and application thereof.The plasma metabolism marker comprises uracil, kynurenine, phenolsulfonic acid, p-cresol, di-high gamma-linolenic acid, atorvastatin, 2-methoxybenzoic acid, carabicycline, nitrogen hydroxyl 2-amino-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5-di-tert-butyl-3, 5- The invention relates to an anti-inflammatory agent which is prepared from 2, 8-dimethylimidazo quinoxaline, dihydroxy phenethyl alcohol O-sulfate, racemization-4-hydroxy-4-O-(beta-D-glucuronate)-all-trans retinol acetate, fructosyl valine, thiaxanthene and acetylpyridine methanol. It is proved for the first time that the 14 plasma metabolites are associated with the Parkinson's disease, a Parkinson's disease prediction method is constructed based on the markers, the prediction result is reliable, and a new way is provided for diagnosis of the Parkinson's disease.

The invention provides cholate-tolerant yellow bacteria and application thereof, and belongs to the field of calculus bovis cultivation. According to the invention, a cholate-tolerant yellow-causing bacterium is obtained through screening, the cholate-tolerant yellow-causing bacterium is classified and named as Escherichia coli NCD04, the bacterial strain is preserved in China Center for Type Culture Collection on August 23, 2024, and the preservation number of the bacterial strain is CCTCC NO: M 20241834. The xanthogenic bacterium provided by the invention is derived from healthy oxgall, has excellent oxgall resistance, is high in activity of produced beta-glucuronidase and high in direct bilirubin conversion rate, can accelerate conversion of bile to calculus bovis, and is used for production of in-vivo or in-vitro artificial calculus bovis.

The present invention relates to a recombinant yeast cell that produces UDP-D-glucuronic acid and / or UDP-N-acetyl-D-glucosamine compared to a wild type cell of the recombinant yeast cell; and optionally, the yield of 3 '-phosphate-adenylate sulfuric acid is increased. The invention also relates to a method for producing heparan sulfate, which comprises a step of culturing the recombinant yeast cell, further relates to an application of the non-invasive recombinant yeast cell for producing heparan sulfate, and finally relates to heparan sulfate obtained by applying the method.

The invention provides an application of atractylis lactone as a beta-glucuronidase inhibitor. Experiments find that atractylenolide can act on active sites of beta-glucuronidase to generate various bonding effects and play an inhibition role, and atractylenolide shows a dose-dependent relationship on activity inhibition of beta-glucuronidase. Furthermore, the atractylenolide can be used as a beta-glucuronidase inhibitor for preventing and treating related diseases (such as drug-induced diarrhea, diabetes mellitus, calculus and the like), and has very good research and application values.

The disclosure relates to a traditional Chinese medicine composition, comprising active ingredients derived from Cornu caprae or Cornu saigae tataricae, Radix scutellariae, Bulbus fritillariae ussuriensis, Radix glycyrrhizae, Radix et rhizoma rhei, Gypsum fibrosum, Calculus bovis artifactus and Lapis Chloriti, the said active ingredients comprise in parts by weight: at least 1600 parts of amino acids; at least 120 parts of gallic acid; at least 130 parts of liquiritin; at least 20 parts of liquiritigenin; at least 400 parts of baicalin; at least 40 parts of oroxyloside; at least 120 parts of wogonoside; at least 280 parts of glycyrrhizic acid; at least 12 parts of chrysin-7-O-β-D-glucoronic acid; at least 50 parts of aloe-emodin-8-O-β-D-glucopyranoside; at least 30 parts of chrysophanol-1-O-β-D-glucopyranoside; at least 45 parts of chrysophanol-8-O-β-D-glucopyranoside; at least 260 parts of hyodeoxycholic acid; at least 150 parts of cholic acid. The traditional Chinese medicine composition in the present invention possess antipyretic, anti-inflammatory and antitussive effects.

The invention concerns a novel microassay device comprising a plurality of pillars functionalised using antibody specific for the isolation of extracellular vesicles (EVs), typically but not exclusively from human blood or cell culture media, and including electrodes for measuring impedance; wherein said pillars are made from, or coated with, a copolymer comprising, as copolymerized units, at least one polythiol monomer ('thiol monomer') and at least one polyalkene / alkyne monomer ('ene' monomer'), wherein the ratio of thiol to alkene / alkyne functional groups in said copolymer has an excess of alkene / alkyne functional groups, optionally from about 100:150 to 100:105; a method for the fabrication of said device; use of the device for tissue-selective isolation of EVs, and / or quantifying the amount of said EVs, and / or assaying the enzyme activity of said EVs, such as that of Cytochrome P450 enzymes or UDP-glucuronosyl transferases or, indeed, any other enzyme(s) contained in the cells or EVs; and a kit of parts including said device.

The invention discloses a gymnadenia conopsea octasaccharide-decaose mixture as well as a preparation method and application thereof, and belongs to the technical field of medicines. The monosaccharide of the octasaccharide-decataccharide mixture of the gymnadenia conopsea comprises N-acetamino galactose, fucose, glucuronic acid or sugar alcohol thereof, galactose, N-acetylglucosamine, dehydrated talose and a sulfate group. The octasaccharide to decataccharide mixture of the gymnadenia conopsea disclosed by the invention can be used for remarkably prolonging the time of activating partial thromboplastin and prothrombin and effectively inhibiting endogenous and common coagulation pathways. The octasaccharide-decaose mixture of the gymnadenia conopsea can be used as a potential endogenous factor X enzyme inhibitor for preparing medicines for treating thrombotic cardiovascular diseases.

The invention discloses enteromorpha oligosaccharide as well as a preparation method and application thereof. The enteromorpha oligosaccharide is prepared by degrading enteromorpha polysaccharide, the polymerization degree is 2-10, the enteromorpha oligosaccharide contains rhamnose, glucose, glucuronic acid and xylose, and the preparation method is simple. By constructing a type 2 diabetes mellitus mouse model, it is verified for the first time that the enteromorpha oligosaccharide can significantly reduce the fasting blood glucose level of the type 2 diabetes mellitus mouse, reduce the insulin content in serum and the glycated serum protein level, improve the blood fat metabolism capability of the type 2 diabetes mellitus mouse, and improve the activity of the enteromorpha oligosaccharide in the type 2 diabetes mellitus mouse. According to the enteromorpha oligosaccharide, the liver glycogen synthesis capacity in the mouse liver is improved, the abnormal liver function of the mouse with the type 2 diabetes mellitus is improved, the safety of the enteromorpha oligosaccharide is high, and the enteromorpha oligosaccharide has a good prospect in the aspect of developing food or drugs with the function of controlling the type 2 diabetes mellitus.

The invention provides a specific chromatogram construction and content determination method of the radix asparagi and radix ophiopogonis decoction preparation and a thin-layer chromatography identification method of traditional Chinese medicine flavor components in the radix asparagi and radix ophiopogonis decoction preparation. The specific chromatogram construction method of the radix asparagi decoction preparation comprises the following steps: step 1, taking mangiferin, quercetin-3-O-glucuronide, baicalin, wogonoside and ammonium glycyrrhizinate reference substances, and adding a solvent to prepare a reference substance solution; step 2, taking an Eupatorium japonicum-Liupu decoction reference sample, and adding a solvent to prepare a test solution; and 3, respectively detecting the reference substance solution and the test solution by using high performance liquid chromatography, and by taking the characteristic spectrum of the reference substance solution as a reference spectrum, selecting a common peak from the characteristic spectrum of the test solution to construct the characteristic spectrum of the radix asparagi decoction preparation.

The invention belongs to the technical field of biology, and discloses a gene of beta-glucuronidase, an amino acid sequence, an expression vector and a host cell of the beta-glucuronidase and application of the beta-glucuronidase in preparation of glycyrrhetinic acid monoglucuronide. The gene of the beta-glucuronidase is connected with an expression vector and is transformed into a saccharomyces cerevisiae cell, so that the saccharomyces cerevisiae engineering strain with high yield of the beta-glucuronidase is successfully constructed. The glycyrrhizic acid can generate a single product glycyrrhetinic acid monoglucuronide under the catalytic action of the enzyme, and no by-product is generated, so that the aim of efficiently, specifically and safely preparing glycyrrhetinic acid monoglucuronide is fulfilled, and the application and development prospect is wide.

The invention provides a complex microbial inoculant for producing beta-glucuronidase and application of the complex microbial inoculant in calculus bovis production, and relates to the technical field of microorganisms. The culture method of the complex microbial inoculant provided by the invention comprises the following steps: culturing lactobacillus ATCC 53103 in an initial culture medium to a logarithmic phase, sterilizing to obtain a complex culture medium, mixing the complex culture medium with nutritional ingredients, inoculating escherichia coli ATCC 25922 and riemerella CCUG 14215, and co-culturing to obtain the complex microbial inoculant. The complex microbial inoculant provided by the invention can generate a large amount of high-activity beta-glucuronidase, so that the efficiency of in-vitro production of calculus bovis can be effectively improved.

The invention relates to the technical field of medicines, and provides sea sodium polysaccharide, a preparation method and application thereof, and an anticoagulant and / or antithrombotic drug of a targeted endogenous coagulation pathway. The sea sodium polysaccharide provided by the invention is fucosylated chondroitin sulfate polysaccharide, the weight-average molecular weight is 90000-130000, the molar ratio of glucuronic acid to N-acetylgalactosamine to fucose is 1: (0.8-1.2): (0.5-0.8), and the mass percentage of sulfate group is 25-40%. The sea sodium polysaccharide provided by the invention can act on a terminal rate-limiting enzyme (iFXase) in an endogenous blood coagulation pathway in a targeting manner, is not obvious in effect on blood coagulation factors in other blood coagulation pathways, realizes the effects of anticoagulation and no bleeding, can be widely applied to acute-stage and recovery-stage treatment of cerebral arterial thrombosis, and has a wide application prospect. The problem of safety of anticoagulant and antithrombotic drugs used by clinical cerebral arterial thrombosis patients is solved, and a new field of research and development of targeted endogenous coagulation pathway rate-limiting enzyme anticoagulant drugs is developed.

The invention provides a method for extracting acacetin-7-O-glucuronide from dracocephalum moldavica, and relates to the technical field of medicine extraction. The method comprises the following steps: heating and extracting dracocephalum moldavica or dracocephalum moldavica products by adopting an alkaline solution, and precipitating the obtained extracting solution under the condition that the pH value is 1-3 to obtain a precipitate extract; mixing n-hexane, ethyl acetate, ethanol and water, and layering to obtain an upper phase solution and a lower phase solution; and dissolving the precipitate extract with a lower-phase solution, carrying out high-speed counter-current chromatography separation on the obtained sample solution, and collecting an acacetin-7-O-glucuronide fraction according to a chromatogram. According to the method, alkali extraction, acid precipitation and high-speed counter-current chromatography are combined, process conditions are optimized, the high-purity monomer of acacetin-7-O-glucuronide in dracocephalum moldavica is rapidly prepared, and the process is simple.

The invention relates to the technical field of scale inhibitors, in particular to a non-phosphorus corrosion and scale inhibitor as well as a compounding method and application thereof, and the non-phosphorus corrosion and scale inhibitor comprises the following components in parts by mass: 10-1000 parts of glucarate or 1-500 parts of glucuronate, 1-300 parts of soluble alkali, 1-500 parts of organic acid and / or organic acid salt, 1-400 parts of corrosion inhibitor and 1-1000 parts of water. According to the phosphorus-free corrosion and scale inhibitor adopting the components and the compounding method and application thereof, the scale inhibition performance of glucarate or glucuronate is greatly improved, and through the efficient Ca < 2 + > resistance performance, the threshold effect and the good synergistic effect among agents after the glucarate / glucuronate is compounded with the organic acid and the corrosion inhibitor, the scale inhibition performance of the phosphorus-free corrosion and scale inhibitor is improved, and the scale inhibition effect of the phosphorus-free corrosion and scale inhibitor is improved. The formula effect of the phosphorus-free corrosion and scale inhibitor is improved, and the water treatment cost is greatly reduced.

The invention provides a method for producing beta-glucuronidase from escherichia coli and application of the beta-glucuronidase, and relates to the technical field of microorganisms. The method provided by the invention comprises the following steps: inoculating Escherichia coli ATCC 25922 on a composite culture medium for pre-culture, and culturing in an electric field environment of 1-10N / C for 12-24h to obtain a mixture containing beta-glucuronidase; wherein the composite culture medium comprises 10-100 [mu] mol / L of ferric citrate, and the concentration of the ferric citrate is increased in stages in the pre-culture process. According to the method, the escherichia coli ATCC 25922 is cultured in the iron-containing culture medium and the low-intensity electric field environment, so that the synthesis of the beta-glucuronidase by the escherichia coli ATCC 25922 can be effectively improved, and the enzyme activity and the enzyme yield of the beta-glucuronidase are improved.

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating urolithiasis and preparation and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials and monomers in parts by weight: 10 to 30 parts of endothelium corneum gigeriae galli, 10 to 30 parts of rhizoma phragmitis, 10 to 30 parts of poria cocos, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of herba cistanche, 10 to 20 parts of herba cepbalanoplosis segeti, 10 to 15 parts of fructus gardeniae, 5 to 10 parts of liquorice root and 1 to 6 parts of gossypotin 8-O-glucuronide. According to the traditional Chinese medicine theory of clearing heat, treating stranguria, dissolving stone and strengthening body resistance, modern pharmacological research is combined, scientific compatibility is carried out through chemical cutting, the synergistic effects of clearing heat, cooling blood, inducing diuresis, treating stranguria, dissolving stone, relieving pain, tonifying kidney and strengthening body resistance are achieved, the preparation process is efficient and controllable, and clinical application is safe and effective.

The invention discloses application of a pharmaceutical composition in preparation of a medicine for treating nephropathy, the nephropathy is at least one of membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and the pharmaceutical composition belongs to the technical field of pharmacy. The pharmaceutical composition is prepared from the following flavonoid components in a mass ratio: the mass ratio of the gossypothelin-8-O-beta-D-glucuronide to the hyperoside to the isoquercitrin to the myricetin to the quercetin-3 '-O-glucoside is 10 to (3.0 to 20) to (2.0 to 18) to (0.2 to 6.0) to (1 to 20). The pharmaceutical composition has obvious effects of preventing and / or treating membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and has relatively good safety.

The present invention discloses a method for constructing a fingerprint of Gualou Niu Bang decoction, relating to the technical field of analytical chemistry. The method is simple and has high precision, stability, and repeatability. Determination revealed that seven components, including geniposide, liquiritin, hesperidin, arctiin, baicalin, melaleucalyptol A-7-O-β-D-glucuronide, and wogonin, can be used as common characteristic peaks in the fingerprint of Gualou Niu Bang decoction for identification research.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention discloses a lutein composition for relieving asthenopia and a preparation method of the lutein composition, and belongs to the field of functional foods. Phycocyanin and kelp polyphenol are mixed and react to obtain modified phycocyanin; fucoidin and beta-glucuronidase are mixed and react to obtain modified fucose; mixing the fish collagen peptide and zinc chloride to react to obtain a collagen peptide-zinc chelate; the xanthophyll siliceous cage compound and the modified phycocyanin are mixed and react to obtain a first compound; mixing and reacting the first compound and modified fucose to obtain a second compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil to obtain a lutein compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil, adding trehalose, and mixing and reacting to obtain a xanthophyll compound; and mixing the xanthophyll compound and maltodextrin to obtain the xanthophyll composition.

The invention discloses a beta-glucuronidase mutant and application thereof, and belongs to the technical field of genetic engineering and protein engineering modification. The beta-glucuronidase mutant disclosed by the invention has the following mutation on the basis of an amino acid sequence as shown in SEQ ID NO.3: T512S or T512A. The catalytic efficiency of the beta-glucuronidase mutant T512S is improved by 13.92 times compared with that of AtGUS (-3t), and the beta-glucuronidase mutant T512S shows remarkable industrial application potential.

The present invention discloses a preparation method of glucurone, which relates to the technical field of esterification reactions. The method comprises the following steps: adding inositol oxidase to an inositol feed solution for conversion to obtain a conversion solution, and successively subjecting the conversion solution to filtration, ion exchange, decolorization, thermal concentration, and lactonization crystallization steps to obtain crude glucurone. The preparation method of the present invention uses inositol as a raw material, and after converting inositol into glucuronic acid solution under the action of an enzyme, adopts filtration, ion exchange, decolorization, thermal concentration, and lactonization crystallization steps to prepare crude glucurone. By adopting the technical solution of the present invention to prepare glucurone, the problems of low extraction rate of crude products, severe operating pressure, strict equipment requirements, and environmental pollution existing in the nitric acid oxidation method using starch as a raw material are solved. At the same time, the present invention uses inositol as a raw material, which is a new process different from the process using starch as a raw material, and has the advantages of low production cost, short cycle, and industrialization feasibility.

The present application relates to the technical field of antibody conjugated drugs, in particular to a drug conjugate with sustained-release property, an antibody conjugated drug and application thereof. The drug conjugate Payload is a payload selected from a drug molecule with cytotoxicity; X is a heteroatom in the payload, selected from O or N; R4 and R5 are independently selected from hydrogen, an alkyl group or other chemical modification groups; R1, R2, R3 and R6 are independently selected from hydrogen, an amino group, a group containing an ether bond, a hydrophilic group, a halogen, an alkyl group or other chemical modification groups; and Glu is a glucuronic acid group. The present application has the advantages of achieving sustained-release effect, increasing stability, avoiding possible non-specific rupture of carbamate bonds in in-vivo circulation, improving the half-life of ADC drugs in blood circulation, reducing toxicity and increasing drug efficacy, and achieving more effective and safe treatment effect due to the sustained-release mechanism which maintains local toxin concentration in a more reasonable killing interval and reduces systemic toxic side effects.

The invention provides application of rhizoma atractylodis macrocephalae polysaccharide in preparation of a medicine for treating diabetes mellitus complicated with steatohepatitis, and belongs to the field of traditional Chinese medicines. The atractylodes macrocephala polysaccharide (APMs) composed of glucose, arabinose, galactose, galacturonic acid and glucuronic acid is prepared through a water extraction and alcohol precipitation method, can be used for treating diabetes mellitus complicated with steatohepatitis, and has a remarkable treatment effect on diabetes mellitus complicated with steatohepatitis; insulin resistance, lipid metabolism disorder, liver inflammation, liver injury and liver fibrosis caused by diabetes mellitus complicated with steatohepatitis can be improved.

The invention relates to the technical field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of various components in Shuanling antidiarrheal granules based on a UPLC-QQQ-MS / MS. The contents of 18 components in the Shuanling antidiarrheal granules are simultaneously determined by using an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer. The 18 components comprise adenosine, gallic acid, protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, liquiritin, ellagic acid, kaempferitrin, narirutin, hesperidin, baicalin, oroxylin A-7-O-beta-D-glucuronide, wogonin, baicalein, wogonin, pachymic acid B and pachymic acid A. The invention further discloses a preparation method of the pharmaceutical composition. Through the UPLC-QTRAP-MS / MS combined technology, the technical prejudice that single component depends on in quality control of the traditional Chinese medicine compound preparation is broken through, the key problems that multiple components in a complex matrix are difficult to separate, low-content components are difficult to detect and the like are solved, efficient, accurate and synchronous determination of 18 components is achieved, and the method is suitable for large-scale popularization and application. A new reference path is opened up for modernized quality control of the traditional Chinese medicine compound preparation.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.